1q21 Gain Combined With High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China

Oncologist - United States
doi 10.1634/theoncologist.2019-0132
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Concomitant Gain of 1q21 and MYC Translocation Define a Poor Prognostic Subgroup of Hyperdiploid Multiple Myeloma

Haematologica
Hematology
2015English

Quantification of Clonal Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Implications for Redefining High-Risk Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2014English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Prognostic Nomogram for the Overall Survival of Patients With Newly Diagnosed Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2019English

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Bortezomib Overcomes the Negative Prognostic Impact of Renal Impairment in a Newly Diagnosed Elderly Patient With Multiple Myeloma: A Case Report

Oncology Letters
Cancer ResearchOncology
2017English

FOXM1 Is a Therapeutic Target in High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Increasing Newly Diagnosed Rate and Changing Risk Factors of HCV in Yanbian Prefecture, a High Endemic Area in China

PLoS ONE
Multidisciplinary
2014English

Time to Plateau as a Predictor of Survival in Newly Diagnosed Multiple Myeloma

American Journal of Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy